Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 1,729 · FY2023 0 · FY2024 0 — 3-yr total 1,729
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company imports and retails biological active food supplements and personal care products.
Subsidiary of Shezghuduli Pasukhismgeblobissazogadoeba Piluet Saipres Limited (100.0%)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 1,487 | 2,305 | 1,995 | 1,234 | 2,085 | 73 | 1,066 | nmf |
| Net Cash used in Investing Activities | 9 | 25 | 37 | 728 | 5 | 150 | 61 | +36.5% |
| Free Cash Flow (OCF − Capex proxy) | 1,478 | 2,280 | 1,958 | 506 | 2,080 | 224 | 1,127 | nmf |
| Net Cash from Financing Activities | 1,065 | 1,322 | 2,729 | 1,471 | 1,975 | 224 | 1,186 | nmf |
| Net Change in Cash (before FX) | 413 | 958 | 770 | 965 | 104 | 1 | 59 | -27.7% |
| Effect of FX on Cash | 129 | 339 | 314 | 357 | 5 | 33 | 92 | -5.5% |
| Net Change in Cash (incl. FX) | 283 | 619 | 456 | 1,322 | 99 | 32 | 33 | nmf |
| Cash at Beginning of Year | 1,056 | 1,340 | 1,959 | 1,503 | 181 | 280 | 248 | -21.5% |
| Cash at End of Year | 1,340 | 1,959 | 1,503 | 181 | 280 | 248 | 215 | -26.3% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →